Helicon Therapeutics, Inc.
Records under this name other than patents Helicon Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Helicon Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,338,405 | Therapeutic piperazines Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,220,775 | Compound Useful for the Treatment of Neuropathic Pain Formerly held Term ended Term ended Apr 9, 2025 · High confidence | Term ended | Term ended Apr 9, 2025 | High confidence |
| US 8,222,243 | Therapeutic isoxazole compounds Formerly held Lapsed on the fee record Ended Jul 17, 2024 · USPTO record | Lapsed on the fee record | Ended Jul 17, 2024 | USPTO record |
| US 7,919,626 | Pyrazole compounds and uses thereof Formerly held Lapsed on the fee record Ended Apr 5, 2023 · USPTO record | Lapsed on the fee record | Ended Apr 5, 2023 | USPTO record |
| US 8,927,546 | Therapeutic piperazines Formerly held Lapsed on the fee record Ended Jan 6, 2023 · USPTO record | Lapsed on the fee record | Ended Jan 6, 2023 | USPTO record |
| US 8,921,399 | Therapeutic isoxazole compounds Formerly held Lapsed on the fee record Ended Dec 30, 2022 · USPTO record | Lapsed on the fee record | Ended Dec 30, 2022 | USPTO record |
| US 7,829,713 | Therapeutic piperazines Formerly held Lapsed on the fee record Ended Nov 9, 2022 · USPTO record | Lapsed on the fee record | Ended Nov 9, 2022 | USPTO record |
| US 8,791,137 | Therapeutic compounds Formerly held Lapsed on the fee record Ended Jul 29, 2022 · USPTO record | Lapsed on the fee record | Ended Jul 29, 2022 | USPTO record |
| US 9,931,318 | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation Formerly held Lapsed on the fee record Ended Apr 3, 2022 · USPTO record | Lapsed on the fee record | Ended Apr 3, 2022 | USPTO record |
| US 9,795,591 | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation Formerly held Lapsed on the fee record Ended Oct 24, 2021 · USPTO record | Lapsed on the fee record | Ended Oct 24, 2021 | USPTO record |